Poor response to clopidogrel: Current and future options for its management

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 3, 2010, Pages 319-331

  Campo, Gianluca ^a   Fileti, Luca ^a   Valgimigli, Marco ^a   Tebaldi, Matteo ^a   Cangiano, Elisa ^a   Cavazza, Caterina ^a   Marchesini, Jlenia ^a   Ferrari, Roberto ^a,b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b IRCCS   (Italy)

Author keywords

Clopidogrel; Multiplate analyzer; Prasugrel; Resistance; VerifyNow

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARC 69931MX; ATORVASTATIN; CANGRELOR; CLOPIDOGREL; E 5555; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; OMEPRAZOLE; PACLITAXEL; PANTOPRAZOLE; PHOSPHOPROTEIN; PLACEBO; PRASUGREL; PRAVASTATIN; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; RAPAMYCIN; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HEART INFARCTION; HEART REINFARCTION; HEMATOMA; HEREDITY; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LEUKOPENIA; LIVER FAILURE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MORTALITY; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEADY STATE; STENT THROMBOSIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TURNOVER TIME; UPREGULATION; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; FORECASTING; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT FAILURE;

EID: 77957954848     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0457-5     Document Type: Review

References (39)

1. ME Bertrand HJ Rupprecht P Urban AH Gershlick 2000 Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 624 629 1:CAS:528:DC%2BD3cXlvFyms7g%3D 10931801
2. G Montalescot G Sideris C Meuleman C Bal-dit-Sollier N Lellouche G Steg M Slama O Milleron JP Collet F Henry Beygui L Drouet 2006 A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes. The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial J Am Coll Cardiol 48 931 938 1:CAS:528:DC%2BD28XpsVWmtbo%3D 10.1016/j.jacc.2006.04.090 16949482 (Pubitemid 44292463)
3. G Patti G Colonna V Pasceri, et al. 2005 Randomized trial of high loading dose of clopidogrel for reduction of periprocedurale myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for reduction of myocardial damage during angioplasty) study Circulation 111 2099 2106 1:CAS:528:DC%2BD2MXjtlKlsbk%3D 10.1161/01.CIR.0000161383.06692.D4 15750189 (Pubitemid 40577905)
4. T Cuisset C Frere J Quilici, et al. 2006 Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting J Am Coll Cardiol 48 1339 1345 1:CAS:528:DC%2BD28XhtVagtLfJ 10.1016/j.jacc.2006. 06.049 17010792 (Pubitemid 44436814)
5. DJ Angiolillo A Fernandez-Ortiz E Bernardo, et al. 2007 Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 1505 1516 1:CAS:528: DC%2BD2sXjvFGgt7s%3D 10.1016/j.jacc.2006.11.044 17418288 (Pubitemid 46517957)
6. JT Brandt SL Close SJ Iturria CD Payne NA Farid CS Ernest DR Lachno D Salazar KJ Winters 2007 Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2429 2436 1:CAS:528:DC%2BD1cXivFGj 10.1111/j.1538-7836.2007. 02775.x 17900275 (Pubitemid 350154353)
7. JS Hulot A Bura E Villard M Azizi V Remones C Goyenvalle M Aiach P Lechat P Gaussem 2006 Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2244 2247 1:CAS:528:DC%2BD28XhtVCgur7I 10.1182/blood-2006-04-013052 16772608 (Pubitemid 44497506)
8. S Tabassome C Verstuyft M Mary-Krause L Quteineh W Drouet N Meneveau PG Steg J Ferrieres N Danchin L Becquemont 2009 Genetic Determinants of Response to Clopidogrel and Cardiovascular Events N Engl J Med 360 363 375 10.1056/NEJMoa0808227
9. P Fontana A Dupont S Gandrille C Bachelot-Loza JL Reny M Aiach P Gussem 2003 Adenosine diphosphate induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 989 995 1:CAS:528:DC%2BD3sXmsVOrs7c%3D 10.1161/01.CIR.0000085073.69189.88 12912815 (Pubitemid 37048230)
10. N Von Beckerath O von Beckerath W Koch M Eichinger A Schoming A Kastrati 2005 P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose Blood Coagul Fibrinolysis 16 199 204 10.1097/01.mbc.0000164429.21040.0a
11. EI Lev RT Patel S Guthikonda D Lopez PF Bray NS Kleiman 2007 Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel Thromb Res 119 355 360 1:CAS:528: DC%2BD2sXhslyqtQ%3D%3D 10.1016/j.thromres.2006.02.006 16581111 (Pubitemid 44918095)
12. WC Lau LA Waskell PB Watkins CJ Neer K Horowitz AS Hopp, et al. 2003 Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 32 37 1:CAS:528:DC%2BD3sXhs1M%3D 10.1161/01.CIR.0000047060.60595.CC 12515739 (Pubitemid 36070929)
13. J Saw SR Steinhubl PB Berger DJ Kereiakes VL Serebruany D Brennan 2003 Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 921 924 1:CAS:528:DC%2BD3sXmsVOrsLs%3D 10.1161/01.CIR.0000088780.57432.43 12925453 (Pubitemid 37048218)
14. J Saw DM Brennan SR Steinhubl DL Bhatt KH Mak K Fox 2007 Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial J Am Coll Cardiol 50 291 295 1:CAS:528:DC%2BD2sXotVans7g%3D 10.1016/j.jacc.2007.01.097 17659194 (Pubitemid 47058889)
15. M Gilard B Arnaud G Le Gal JF Abgrall J Boschat 2006 Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin (letter) J Thromb Haemost 4 2508 2509 1:CAS:528:DC%2BD28Xht1yjtbfJ 10.1111/j.1538-7836.2006.02162.x 16898956 (Pubitemid 44575451)
16. M Gilard B Arnaud JC Cornily 2008 Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 256 260 1:CAS:528:DC%2BD1cXpt1Gksg%3D%3D 10.1016/j.jacc.2007.06.064 18206732
17. T Cuisset C Frere J Quilici 2009 Comparison of omeprazole and pantoprazole influence on high 150-mg clopidogrel maintenance dose. The PACA (proton pump inhibitors and clopidogrel association) prospective randomized trial J Am Coll Cardiol 54 1149 1153 1:CAS:528:DC%2BD1MXht1GntbbK 10.1016/j.jacc.2009.05.050 19761935
18. PM Ho TM Maddox L Wang 2009 Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 937 944 1:CAS:528:DC%2BD1MXivFejt7g%3D 10.1001/jama.2009.261 19258584
19. D Juurlink T Gomes D Ko 2009 A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 713 718 19176635
20. ML O'Donoghue E Braunwald EM Antman 2009 Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 989 997 10.1016/S0140-6736(09)61525-7 19726078
21. PA Gurbel KP Bliden W Samara JA Yoho K Hayes MZ Fissha US Tantry 2005 Clopidogrel effect on platelet REactivity in patients with stent thrombosis results of the CREST study J Am Coll Cardiol 46 1827 1832 1:CAS:528: DC%2BD2MXht1SrtbzL 10.1016/j.jacc.2005.07.056 16286166 (Pubitemid 41579803)
22. W Hochholzer D Trenk HP Bestehorn B Fischer CM Valina M Ferenc M Gick A Caputo HJ Büttner FJ Neumann 2006 Impact of the Degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 1742 1750 1:CAS:528:DC%2BD28XhtFOjtb7E 10.1016/j.jacc.2006.06.065 17084243 (Pubitemid 44648629)
23. PA Gurbel KP Bliden K Guyer PW Cho KA Zaman RP Kreutz AK Bassi US Tantry 2005 Platelet reactivity in patients and recurrent events post-stenting results of the prepare post-stenting study J Am Coll Cardiol 46 1820 1826 1:CAS:528:DC%2BD2MXht1SrtbzK 10.1016/j.jacc.2005.07.041 16286165 (Pubitemid 41579802)
24. P Buonamici R Marcucci A Migliorini GF Genuini A Santini R Paniccia G Moschi AM Gori R Abbate D Antoniucci 2006 Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisD J Am Coll Cardiol 48 2318 2319
25. R Marcucci AM Gori R Paniccia B Giusti S Valente C Figlioli P Buonamici D Antoniucci R Abbate GF Genuini 2009 Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay A 12-month follow-up Circulation 119 237 242 10.1161/CIRCULATIONAHA.108.812636 19118249
26. G Patti A Nusca F Mangiacapra L Gatto A D'Ambrosio G Di Sciascio 2008 Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study J Am Coll Cardiol 52 1128 1133 1:CAS:528:DC%2BD1cXhtFersr7I 10.1016/j.jacc.2008.06.038 18804738
27. P Barragan JL Bouvier PO Roquebert 2003 Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 59 295 302 10.1002/ccd.10497 12822144 (Pubitemid 36792384)
28. B Blindt K Stellbrink A de Taeye R Muller P Jiefer E Yagmur C Weber M Kelm R Hoffmann 2007 The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis Thromb Haemost 98 1329 1334 1:CAS:528:DC%2BD1cXnsV2nug%3D%3D 18064332
29. D Sibbing S Braun T Morath 2009 Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 849 856 1:CAS:528:DC%2BD1MXlslagsrk%3D 10.1016/j.jacc.2008.11.030 19264241
30. DJ Angiolillo SB Shoemaker B Desai H Yuan RK Charlton E Bernardo MM Zenni LA Guzman TA Bass MA Costa 2007 Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study Circulation 115 708 716 1:CAS:528:DC%2BD2sXhtlGqtbg%3D 10.1161/CIRCULATIONAHA.106.667741 17261652 (Pubitemid 46294761)
31. MJ Price PB Berger DJ Angiolillo PS Teirstein JF Tanguay DE Kandzari CP Cannon EJ Topol 2009 Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial Am Heart J 157 818 824 1:CAS:528:DC%2BD1MXkslGns78%3D 10.1016/j.ahj.2009.02.012 19376306
32. L Bonello L Camoin-Jau S Arques C Boyer D Panagides O Wittenberg MC Simeoni P Barragan F Dignat-George F Paganelli 2008 Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance a multicenter randomized prospective study J Am Coll Cardiol 51 1404 1411 1:CAS:528:DC%2BD1cXktlCqsb8%3D 10.1016/j.jacc.2007.12.044 18387444 (Pubitemid 351447314)
33. B Aleil G Rochouxs JP Monassier JP Cazenave C Gachet 2006 Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogre: a report of three cases J Thromb Haemost 5 879 881 10.1111/j.1538-7836.2007.02338.x
34. G Campo M Valgimigli D Gemmati G Percoco L Catozzi A Frangione F Federici F Ferrari M Tebaldi S Luccarelli G Parrinello R Ferrari 2007 Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? evidence from a clopidogrel-to-ticlopidine crossover study J Am Coll Cardiol 50 1132 1137 1:CAS:528:DC%2BD2sXhtVCmu7bO 10.1016/j.jacc.2007.04.092 17868803 (Pubitemid 47375009)
35. T Cuisset C Frere J Quilici PE Morange JP Mouret L Bali PJ Moro M Lambert MC Alessi JL Bonnet 2008 Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study JACC Cardiovasc Interv 1 649 653 10.1016/j.jcin.2008.08.018 19463379
36. M Valgimigli G Campo N De Cesare E Meliga P Vranckx A Furgieri DJ Angiolillo M Sabatè M Hamon A Repetto S Colangelo S Brugaletta G Parrinello G Percoco R Ferrari 2009 Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 119 3215 3222 1:CAS:528:DC%2BD1MXnsFyiurY%3D 10.1161/CIRCULATIONAHA.108.833236 19528337
37. SD Wiviott D Trenk AL Frelinger M O'Donoghue FJ Neumann AD Michelson DJ Angiolillo H Hod G Montalescot DL Miller JA Jakubowski R Cairns SA Murphy CH McCabe EM Antman E Braunwald 2007 Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial Circulation 116 2923 2932 1:CAS:528:DC%2BD2sXhsVWjsr7N 10.1161/CIRCULATIONAHA.107.740324 18056526 (Pubitemid 350291199)
38. SD Wiviott E Braunwald CH McCabe G Montalescot W Ruzyllo S Gottlieb FJ Neumann D Ardissino S De Servi SA Murphy J Riesmeyer G Weerakkody CM Gibson EM Antman 2009 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Eng J Med 357 2001 2015 10.1056/NEJMoa0706482
39. L Wallentin RC Becker A Budaj CP Cannon H Emanuelsson C Held J Horrow S Husted S James H Katus KW Mahaffey BM Scirica A Skene PG Steg RF Storey RA Harrington 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045 1057 1:CAS:528:DC%2BD1MXhtFaltL%2FJ 10.1056/NEJMoa0904327 19717846